Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069291 | 0.74 | MEN1 (0.36) | MAPK1L3MBTL1MAPTKMT2AMEN1 | |
| SCHEMBL18824893 | 0.71 | L3MBTL1 (0.46) | MAPK1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL28330381 | 0.71 | L3MBTL1 (0.46) | L3MBTL1NPSR1KDM4E | |
| SCHEMBL21855440 | 0.70 | IKBKB (0.46) | MAPK1L3MBTL1MAPTNPSR1KDM4E | |
| SCHEMBL22395426 | 0.70 | L3MBTL1 (0.45) | L3MBTL1MAPTNPSR1KDM4EALOX15 | |
| SCHEMBL28330383 | 0.69 | CA12 (0.50) | MAPK1L3MBTL1KMT2AMEN1NPSR1 | |
| SCHEMBL17362675 | 0.67 | L3MBTL1 (0.42) | MAPK1L3MBTL1MAPTHIF1ANPSR1 | |
| SCHEMBL312146 | 0.66 | L3MBTL1 (0.60) | L3MBTL1KMT2AMEN1KDM4ETP53 | |
| SCHEMBL31589851 | 0.66 | NPSR1 (0.43) | MAPK1L3MBTL1MAPTHIF1ANPSR1 | |
| SCHEMBL11434003 | 0.66 | PSMD14 (0.56) | MAPK1MAPTKMT2AMEN1PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1381366-B9 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1381366-B1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1381366-A4 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-16 | — | — | EP | disclosed |
| US-6825201-B2 | ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1381366-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030096825-A1 | Indole, azaindole and related heterocyclic amidopiperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-05-22 | — | — | US | disclosed |
| WO-2002085301-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096825-A1 | Indole, azaindole and related heterocyclic amidopiperazine derivatives | IDO1, IDO2, INMT | MAPK1 4326/4885L3MBTL1 4731/4885MAPT 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.